Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;197(10):950-952.
doi: 10.1007/s00066-021-01823-z. Epub 2021 Jul 26.

[Moderate dose de-escalation of cisplatin-based chemoradiation for HPV-associated oropharyngeal carcinoma : Results of the NRG-HN002 trial]

[Article in German]
Alexander Rühle  1   2 , Nils H Nicolay  3   4
Affiliations
Comment

[Moderate dose de-escalation of cisplatin-based chemoradiation for HPV-associated oropharyngeal carcinoma : Results of the NRG-HN002 trial]

[Article in German]
Alexander Rühle et al. Strahlenther Onkol. 2021 Oct.
No abstract available

PubMed Disclaimer

Comment on

  • Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
    Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, Truong MT, Kong C, Jordan R, Subramaniam RM, Yao M, Chung CH, Geiger JL, Chan JW, O'Sullivan B, Blakaj DM, Mell LK, Thorstad WL, Jones CU, Banerjee RN, Lominska C, Le QT. Yom SS, et al. J Clin Oncol. 2021 Mar 20;39(9):956-965. doi: 10.1200/JCO.20.03128. Epub 2021 Jan 28. J Clin Oncol. 2021. PMID: 33507809 Free PMC article. Clinical Trial.

References

    1. Rühle A, Grosu A-L, Nicolay NH. De-escalation strategies of (chemo)radiation for head-and-neck squamous cell cancers—HPV and beyond. Cancers. 2021;13:2204. doi: 10.3390/cancers13092204. - DOI - PMC - PubMed
    1. Chera BS, Amdur RJ, Green R, Shen C, Gupta G, Tan X, et al. Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2019;37:2661–2669. doi: 10.1200/JCO.19.01007. - DOI - PMC - PubMed
    1. Chera BS, Amdur RJ, Tepper J, Qaqish B, Green R, Aumer SL, et al. Phase 2 trial of de-intensified chemoradiation therapy for favorable-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015;93:976–985. doi: 10.1016/j.ijrobp.2015.08.033. - DOI - PubMed
    1. Chera BS, Amdur RJ, Tepper JE, Tan X, Weiss J, Grilley-Olson JE, et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer. 2018;124:2347–2354. doi: 10.1002/cncr.31338. - DOI - PubMed
    1. Oliva M, Huang SH, Xu W, Su J, Hansen AR, Bratman SV, et al. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. Eur J Cancer. 2019;118:112–120. doi: 10.1016/j.ejca.2019.06.019. - DOI - PubMed

LinkOut - more resources